Innovation Pharmaceuticals Inc (IPIX)

[wsbc]

here's one: https://www.fiercebiotech.com/biotech/affimed-lands-big-backloaded-immunotherapy-deal-genentech-sending-its-stock-into-overdrive?mkt_tok=eyJpIjoiTkRFeU1EUmxaV1ZpWTJWaCIsInQiOiJpN0lydDVrdFNoR0VjQUNkVDg5R3M1OGRoNFc0eWhcL1FOaGhFTWY3TWdQNTdsdWpuWXdReDhiUWtRYlBORFB5ZVZ3K1hzS25EUW0zUEF4aitCMnkrcTNSQUM2Z2V1ZlhzakFLWnhDNlZXUWh2aEJNb3Z1VE5meWI4VyswWVFwNUMifQ%3D%3D&mrkid=74197490

Milestones and upfront payments for further development seem to be closer to the standard. There have been a handful of outright buyouts over the last 8mo or so, but I guess it depends on the pipeline and progress.

Not sure why people are saying that 'a buyout depends on the cap', when the cap reflects nothing related to value of the products within this sector attributable to the respective companies in question. If Bril-OM has a street value over the course of 10yrs of X, based on competitor sales/projected sales, then how on earth does that reflect on a market-cap price for a company if the SP doesn't reflect the value of the actual product. If an M&A is being considered, assets are calculated etc, and values are assessed. Patents ARE value with this stuff. They're not reflected in the SP though, mostly because this is a PRE-revenue company. People seem to be forgetting this.

I don't understand the 'logic' behind so many arguments on here, and I guess the waiting game and lack of updates is making some folks a little nutty. I get it.